Addressing Myelotoxicity as a Consequence of Treatment for Extensive-Stage Small Cell Lung Cancer : Episode 13
EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial Data
In the fifth interview of the series, medical oncologist and hematologist Dr. Jerome H. Goldschmidt from Blue Ridge Cancer Care elaborates on the rationale for use of CDK4/6 inhibitors such as trilaciclib for prevention of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), and touches on recently presented data on trilaciclib.
EP: 1.EP. 1: Extensive-Stage Small Cell Lung Cancer Treatment Landscape
EP: 2.EP. 2A: Treatment Challenges and Unmet Needs in Extensive-Stage Small Cell Lung Cancer
EP: 3.EP. 2B: Challenges Affecting the Management of Extensive-Stage Small Cell Lung Cancer
EP: 4.EP. 3: Management of Extensive-Stage Small Cell Lung Cancer Treatment-Related Events
EP: 5.EP. 4A: The Role of Trilaciclib in the Management of Chemotherapy-Induced Myelosuppression in SCLC
EP: 6.EP. 4B: Considering Chemotherapy-Induced Myelosuppression and the Impact of Trilaciclib on Its Management
EP: 7.EP. 5: Clinical Trial Evidence for the Myeloprotective Benefit of Trilaciclib for Chemotherapy-Induced Myelosuppression
EP: 8.EP. 6A: Benefits of Using Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer in Clinical Practice
EP: 9.EP. 6B: Clinical Experience With Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer
EP: 10.EP. 7: Clinical Trial Evidence for Chemoprotectant Benefit of ALRN-6924 for Chemotherapy-Induced Myelosuppression
EP: 11.EP. 8A: Considerations for Reactive and Proactive Approaches to the Management of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer
EP: 12.EP. 8B: Reactive and Proactive Treatment Approaches for the Management of Chemotherapy-Induced Myelosuppression
Now Viewing
EP: 13.EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial Data
EP: 14.EP. 10A: Impact of Trilaciclib on Chemotherapy-Induced Myelosuppression in Patients with ES-SCLC
EP: 15.Episode 10B: Impact of Trilaciclib on Chemotherapy Induced Myelosuppression (CIM) in ES-SCLC
EP: 16.Episode 11A: Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC Treatment
EP: 17.Episode 11B: The Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC Treatment
EP: 18.EP 12A: Managing Thrombocytopenia in Patients receiving Chemotherapy for ES-SCLC
EP: 19.EP 12B: Management of Chemotherapy Induced Myelosuppression (CIM) in ES-SCLC
Related Videos
Related Content
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Article
Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
